Pandemic darlings Moderna, BioNTech are now on two different paths
-
最新报道：Moderna and BioNTech stocks show diverging strategies as COVID vaccine demand wanes, with Moderna focusing on mRNA flu shots and BioNTech investing in cancer treatments. Moderna's shares rose 3% after announcing positive Phase 3 trial results for its influenza vaccine, while BioNTech fell 5% as investors questioned its pivot to oncology. Analysts note both companies face challenges transitioning from pandemic windfalls to sustainable growth, with Moderna targeting a $7 billion annual flu vaccine market and BioNTech betting on personalized cancer therapies.
下一篇
Joint venture AlUnity launches German-regulated Euro stablecoin EURAU, issued on the Ethereum network
- AlUnity, a joint venture between DWS, Galaxy, and Flow Traders, has launched EURAU, a euro...
24小时热点
热点专题
407106